PHAXIAM: Publication of Financial Results for the Third Quarter of 2024

PHAXIAM Therapeutics has revealed a cash position of €5.7 million as of September 30, 2024, confirming its ability to finance its projects until March 2025. This situation results from the €7.8 million capital increase carried out in early July. Despite these advances, the company is exploring various financing options to extend its economic visibility, such as cost reductions or non-dilutive financing.

On the clinical front, PHAXIAM is actively preparing to launch the global GLORIA Phase II study on osteoarticular infections, a project approved by the FDA. The company aims to begin recruiting participants as early as the first quarter of 2025. These initiatives aim to establish PHAXIAM as a major player in phage therapy, in particular through its ongoing projects, such as compassionate treatments and the PhagoDAIR study, the results of which are expected at the end of 2024.